Arndt Vogel, MD

Arndt Vogel, MD, is a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre

Articles by Arndt Vogel, MD

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

ByArndt Vogel, MD

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma

ByArndt Vogel, MD

September 28th 2019

Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.

Arndt Vogel, MD

Articles by Arndt Vogel, MD

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies